Losartan Potassium is an angiotensin II receptor blocker indicated for hypertension and diabetic nephropathy in type 2 diabetes. We supply it to US manufacturers of tablets and fixed-dose combinations.
Data from PubChem (CID 11751549) and FDA’s substance registry
CAS number
124750-99-8
Molecular formula
C22H22ClKN6O
Molecular weight
461.0g/mol
FDA UNII
IUPAC name
potassium [2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
InChIKey
OXCMYAYHXIHQOA-UHFFFAOYSA-N
- Appearance
- White to off-white, free-flowing crystalline powder.
- Solubility
- Freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents such as acetonitrile and methyl ethyl ketone.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A tetrazole sartan. Since the 2018 recalls, a nitrosamine risk assessment and an azido impurity statement are standard requests for every source.
On the US market
- Reference product
- CozaarNDA 020386
- Approved ANDAs
- 16 with a marketed product
- Approved forms and strengths
- Tablet 25 mg, 50 mg, 100 mg
- Oral suspension 10 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com